Cancer cells have two possible ways of predisposing to platelet activation: (1) direct adhesion of the cancer cell to platelets and (2) the production of molecules that lead to platelet activation by tumour cells (i.e., interleukin-6, ADP, thrombin, matrix metalloproteinases). This evidence concerns the gene WDTC1 and cancer.